Combination of Ru(ii) complexes and light: new frontiers in cancer therapy.

Mari C, Pierroz V, Ferrari S, Gasser G. · 2015

Read Combination of Ru(ii) complexes and light: new frontiers in cancer therapy. by Mari C, Pierroz V, Ferrari S, Gasser G. (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5639435.txt.

Introduction

Mari and co-authors wrote a perspective article in Chemical Science. It surveys ruthenium complexes paired with light against cancer. Ruthenium compounds have drawn interest for decades. Two were in phase II trials as drug candidates. Their shapes can be tuned toward chosen cell targets. They also tend to harm the body less than platinum drugs.

Light gives doctors control over when and where drugs act. In photodynamic therapy, a sensitizer makes toxic oxygen species under light. In photoactivated chemotherapy, light frees an active drug instead. It can eject ligands or crosslink DNA. The article covers recent gains in both fields. It favors compounds tested in cells with known action.

Catalog record

CREATORMari C, Pierroz V, Ferrari S, Gasser G.
YEAR2015
COLLECTIONPAPERS
FORMATTXT
FILE SIZE99 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5639435

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Combination of Ru(ii) complexes and light: new frontiers in cancer therapy By Cristina Mari, Vanessa Pierroz, Stefano Ferrari, Gilles Gasser Published in: Chemical Science DOI: 10.1039/c4sc03759f ABSTRACT In this perspective article, we present the recent achievements in the application of ruthenium complexes as photosensitizers and as photoactivatable prodrugs. INTRODUCTION The biological activity of ruthenium (Ru) compounds has been known for decades.1–3 Two Ru complexes are currently in phase II clinical trials (NAMI-A and KP1339) as anticancer drug candidates and a third one, RAPTA-C, is progressing towards clinical trials (see Fig. 1 for the structures of these compounds).4–10 The increasing interest in the biological behavior of Ru compounds is due to their appealing physico-chemical properties. Among others, such complexes can have different geometries (e.g. tetrahedral or octahedral) allowing for the design of compounds with a specific cellular target (e.g. proteins). Hence, the rigid and well-defined spatial arrangement of a series of Ru complexes has enabled the preparation of highly potent and selective enzyme inhibitors. The group of Meggers has notably demonstrated such a concept with kinase inhibitors.2,11,12 Other attractive features of Ru complexes include their generally lower systemic toxicity compared to platinum complexes and their higher cellular uptake, thanks to the specific transport of ruthenium inside cells by transferrin.13 Of utmost importance, ruthenium complexes can easily be obtained in two oxidation states (ii and iii) and are prone to ligand exchange. Such properties have been found to play a pivotal role in the mode of action of both NAMI-A and KP1339.14 Ru(iii) complexes are thus prodrugs – meaning that the compound which is administered to the patient is not the active species. Ru(iii) complexes are reduced into a more active Ru(ii) form when localized in an hypoxic environment, which is a property characteristic of tumors.6 This phenomenon is normally referred to as “activation by reduction” and was also exploited for the in situ activation of Pt-based anticancer drug candidates, like satraplatin.15 [Figure: Structures of NAMI-A, KP1339, KP1019 and RAPTA-C.] Nowadays, the use of the “prodrug approach” is very appealing to reduce the systemic toxicity of a drug candidate.16 In order to activate the prodrugs, two different kinds of stimuli can be employed, namely an internal stimulus (reducing cellular conditions, hypoxia, enzymatic reactions, etc.) or an external stimulus (magnetic field, temperature, light, etc.). The first approach, however, presents a significant disadvantage, in that it completely relies on intracellular parameters. In other words, once the prodrug is injected into the patient, physicians have no more control over the fate of the compound. On the contrary, this is exactly the kind of control that can be achieved using an external stimulus. The latter indeed provides complete spatial and temporal control over the generation of the toxic molecule. As of today, the most commonly applied technique to induce the formation of active species is via light irradiation.15,17,18 The light-mediated activation of prodrugs in the field of anticancer research can be generally divided into two categories: photodynamic therapy (PDT) and photoactivated chemotherapy (PACT). PDT relies mainly on the generation of the toxic reactive oxygen species (ROS) singlet oxygen (1O2). On the other hand, PACT exploits different mechanisms to induce cell death such as ligand ejection, DNA crosslinking and caging approaches. In this perspective article, we intend to give an overview of recent progress in the application of ruthenium complexes in both PDT and PACT, focusing particularly on those compounds for which an in vitro evaluation of the biological activity has been performed and the mechanism of action (partially) unveiled. Notably, these topics have been partially reviewed in the past but an article covering all subjects is, to the best of our knowledge, currently missing.17–26 RUTHENIUM COMPLEXES AS PHOTOSENSITIZERS IN PDT Photodynamic therapy is an approved medical technique, which is applied in dermatology for the treatment of several diseases such as acne or psoriasis and in ophthalmology for age-related macular degeneration. Since relatively recently, this technique has been used for the treatment of some types of cancer. For example, Photofrin® (Fig. 2), the only FDA-approved PDT drug, is employed to treat esophageal and non-small cell lung cancers. In the UK, on the other hand, there are several photoactive agents which are clinically approved (i.e. Foscan®, Fig. 2) to treat a wide range of cancer types, from skin to internal organs.27,28 [Figure: Structures of porphyrin-based approved PDT agents.] More specifically, PDT relies on the synergistic activity of an ideally non-toxic molecule called a photosensitizer (PS), light and molecular oxygen. The PS is administrated to the patient either locally or systemically. Upon light irradiation at a wavelength in its range of absorption, the PS is able to reach its singlet excited state 1PS* (Fig. 3). Very importantly, the PS must then undergo an intersystem crossing (ISC) so that the excited state has a triplet character (3PS*). At this point, PDT relies on two different mechanisms called Type I and Type II. A Type I reaction consists of an electron or proton transfer from the triplet excited state of the PS to the surrounding biological substrates (or the other way around). This leads to the formation of radicals that can further interact with molecular oxygen to form ROS such as superoxide, hydroxyl radicals or peroxides. At the same time, an energy transfer from the triplet excited state of the PS to molecular oxygen in its ground triplet state (3O2) can occur (a Type II reaction). In this case, singlet oxygen (1O2) is generated. 1O2 is a very reactive form of oxygen with an estimated half life of 40 ns in a biological environment.27 Consequently, it will rapidly react just with the surrounding biomolecules, generating topical cellular damage that can ultimately lead to cell death. PSs which are nowadays applied in clinics mainly rely on the Type II mechanism of action.29 [Figure: Mechanisms of action of PDT.] PDT is a very appealing medical technique due to its intrinsic selectivity. The toxic species are generated just at the site of light irradiation, with complete spatial and temporal control. Furthermore, due to the very fast reactivity of 1O2, damage is limited to the irradiated areas. The outcomes of PDT treatment depend on the performance of the PS but also on other very important factors (e.g. the light component, the in vivo dosimetry or the oxygen tension). To be clinically applicable, a PS should, among other requirements, (i) localize mainly (ideally only) in cancer cells; (ii) should be non-toxic in the absence of light, while displaying strong phototoxicity. This behavior is normally described by the so-called phototoxic index (PI), defined for a compound as the ratio of its IC50 in the dark to its IC50 upon light irradiation. Finally, the PS (iii) should be excited in the red or near-IR region of the spectrum (>600 nm). This last requirement is very important to avoid cytotoxicity deriving from high energy light irradiation. In addition, the use of long wavelength light allows for a deeper penetration through the human tissues.21,30 The great majority of PSs that are currently applied in clinics are based on a cyclic tetrapyrrolic scaffold. The photophysical and biological characteristics of porphyrins, phthalocyanines and chlorins match the requirements for a PDT agent relatively well. On the other hand, their performances are also limited

Read the complete text